The Conversation (0)
Novartis Pharmaceuticals Canada (Novartis) today announced it is investing $1.2 million to collaborate with the Alberta government to research multiple sclerosis (MS).
Novartis Pharmaceuticals Canada (Novartis) today announced it is investing $1.2 million to collaborate with the Alberta government to research multiple sclerosis (MS).
As quoted in the market news:
“This investment is a milestone for MS research in Alberta, which has one of the highest prevalence rates for the disease in the world,” said Dr. Riad Sherif B., President of Novartis Pharmaceuticals Canada Inc. “Novartis commends the Alberta government for taking a proactive and collaborative approach to investing in the life sciences. We will bring our expertise in MS and neurosciences to this collaboration to support advances that will contribute to improving the lives of Albertans with MS.”
Click here for the full press release by Novartis Pharmaceuticals Canada